Technetium (99mTc) medronic acid
|Chemical and physical data|
|Formula||CH6O6P2 • x99mTc|
Technetium (99mTc) medronic acid (MDP) is a pharmaceutical product used in nuclear medicine to localize bone metastases as well as other diseases that can alter the natural turn-over in the bone by bone scintigraphy.
99mTc-MDP must be prepared in a radiopharmacy. It is usually supplied as a "cold kit" to which radioactive 99mTc from a generator is added. Kit composition may vary between suppliers, but contents typically includes medronic acid, stannous chloride dihydrate and sometimes ascorbic acid. Pertechnetate, eluted from the generator is added to the kit vial, which is swirled and left to stand. The labelling efficiency, an indication of how much 99mTc remains in pertechnetate form rather than bound to the MDP, can be measured using chromatography.
- Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer
- FDA Label: MDP Multidose Utilipack
- KEGG Drug: D02029
- "List of labelling kits for the preparation of a technetium-99m labelled bone scanning agent". Human Health Campus. IAEA. Retrieved 3 March 2017.
- "MDP Bracco" (PDF). Bracco Diagnostics. Retrieved 3 March 2017.
- "Kit for the Preparation of Technetium Tc 99m Medronate for Injection" (PDF). Pharmalucence. Retrieved 3 March 2017.
- "TechneScan MDP Kit for the Preparation of Technetium Tc 99m Medronate Package Insert" (PDF). Mallinckrodt Medical. Retrieved 3 March 2017.
- Mather, SJ; Ellison, D (May 1990). "Reduction-mediated technetium-99m labeling of monoclonal antibodies.". Journal of nuclear medicine. 31 (5): 692–7. PMID 2341907.
|This pharmacology-related article is a stub. You can help Wikipedia by expanding it.|